Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Oncolytic Virus Cancer Therapy Market Snapshot (2023 to 2033)

The global oncolytic virus cancer therapy market is expected to be valued at US$ 22.86 Million in 2023 and is projected to exhibit a CAGR of 27% from 2023 to 2033. Overall, the industry is projected to reach a market value of US$ 250 Million as of 2033.

Oncolytic viruses (OVs), which have recently been identified as an effective anticancer tactic, are a kind of virus that can imitate selectively in tumor cells and constrain their development. OVT is a cancer treatment that employs a virus that can reconstruct itself to kill cancerous cells. There are multiple virus species, but not all of them can be engineered to be oncolytic viruses (OV).

The percentage of cancer cases worldwide has increased exponentially as a result of poor lifestyle decisions and visibility to carcinogens in various forms. This has prompted pharmacological companies to increase their investments in advanced therapeutics. Oncolytic virus cancer therapy has been a market forerunner. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute Details
Expected Market Value (2023) US$ 22.86 Million
Anticipated Forecast Value (2033) US$ 250 Million
Projected Growth Rate (2023 to 2033) 27% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Oncolytic Virus Cancer Therapy Demand Analysis vs. Forecast 2023 to 2033

Oncolytic research has gained popularity in recent years. During the past decade, the number of articles on oncolytic virus therapy studies enhanced by 395%. The oncolytic virus cancer therapy market witnessed enormous growth potential, and over 35 companies conducted clinical trials in this area. As a result, the market experienced high demand in the historical period.

The market for oncolytic virus therapies is expected to evolve in the coming years as a result of enhanced patient outcomes, diagnosis of cold tumors, a rich burgeoning pipeline, and easy production and administrative structure, which will permit drug companies to broaden their market penetration. Companies and academics are cooperating to evaluate obstacles and identify opportunities for oncolytic virus therapies Research and Development. The therapies in development are centered on novel strategies for treating/improving disease symptoms.

Which are Some Prominent Drivers of the Oncolytic Virus Cancer Therapy Market?

Administration awareness programs for early cancer detection drive Industry Growth

Governments in various developing regions have taken initiatives to increase consciousness about different cancer causes. To decrease death and morbidity rates, government agencies in developed and developing nations are performing education programs to inspire people to seek early diagnosis of cancer, which is anticipated to broaden the stream of patients who will be eligible for numerous new therapies.

For example, in the United Kingdom, Public Health England, an executive agency of the Department of Health and Social Care, launched the Be Clear on Cancer campaign to promote early cancer detection by increasing public awareness. Increasing awareness is likely to spur demand for cutting-edge cancer treatment and innovative treatments, with melanoma and breast cancer being the two most common cancers.

Surging Cancer Incidences around the world are fostering a Positive Perspective

Burgeoning cancer occurrences around the world are generating a positive perspective for the market. Because of their potent anti-tumor characteristics and ability to precisely target tumors without injuring adjacent tissues, oncolytic virus therapies are frequently used to treat a variety of cancers, including glioblastoma, breast, lung, and prostate cancer.

In line with this, the therapy's ubiquitous use to cure a wide variety of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is boosting overall growth. Besides that, increasing patient concerns about the negative side effects of various cancer treatment options, such as invasive surgery, radiotherapy, chemotherapy, and immunotherapeutic, are driving market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Treatment Side Effects Could Constrain Future Growth

Because oncolytic viruses have the ability to infect tissue and activate immune defense activity systems, they may cause antibodies that attack healthy cells, increasing the probability of infection. Possible adverse effects of the treatment, such as fever, shivers, dizziness, exhaustion, flu-like symptoms, and pain, may impede future growth, as patients may cautiously weigh these factors before desiring virus treatment.

Furthermore, a disparity in the demand and availability of resources necessary for the therapies may inhibit the service's overall growth and share. As an outcome, critical industrial participants and shareholders must hold these factors into account before investing in the market.

Region-Wise Insights

What Makes Asia Pacific the Largest Market for Oncolytic Virus Cancer?

Pharmaceutical companies are driving the Asia Pacific Market

The Asia Pacific region will hold the largest ownership stake in the Oncolytic Virus Cancer Therapy Market owing to a significant increase in the number of firms manufacturing medications for cancer treatment. As nations like China and Japan introduce breakthroughs into the market, the oncolytic virus therapy market is witnessing a rise in revenue and earnings.

Shanghai Sunway Biotech of China will contribute to market developments with the highest market share. The total oncolytic virus cancer therapy market share in Japan was US$ 2 Million in 2022, and it is anticipated to increase during the study period.

Why is North America Considered a Lucrative Region for the Oncolytic Virus Cancer Therapy Market?

North America is anticipated to grow at a Rapid Pace

North America is predicted to be the most valuable region for the worldwide oncolytic virus cancer therapy market over the upcoming years, with a substantial rate over the forecast period, owing to the region's high incidence of cancer, particularly melanoma cancer.

Furthermore, the region's significant presence of major producers and higher incidence of distributor sponsorship contribute to the greater accessibility of the oncolytic virus cancer therapy market. In 2021, the total market value for oncolytic virus therapies in the United States was US$ 8.5 Million, and this figure is expected to grow during the study period.

Furthermore, the market in North America is expected to expand at the fastest rate during the forecast timeframe, with a CAGR of 29.5%. Adequate spending for cancer research in the region, preceded by the existence of robust medical infrastructure in nations like the United States, is among the significant factors expected to fuel the region's overall growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which End-User Segment Will Generate the Highest Market Revenue?

Hospitals to remain Primary Centers for disbursing Oncolytic Virus Cancer Therapy

Due to an expansion in the number of hospitals curing disease in developing nations, the hospital segment held the highest revenue share in 2021. Furthermore, increased patient prominence on effective and prompt disease management, as well as government investment in medical infrastructure, are cruising the growth of this segment.

Which Application Segment Will Hold the Highest Market Share?

Treatment for Sold Tumour Breast Cancer to acquire Precedence

The oncolytic virus cancer therapy market is divided into two applications: solid tumors and melanoma. With the solid tumor category, treatment for breast cancer is likely to account for the lion’s share. Breast cancer is the second most frequently diagnosed cancer worldwide, and current treatments are inadequate to heal metastatic breast cancer, as it is frequently affiliated with significant side effects that devastate patients' life quality.

Oncolytic Virus Cancer Therapy has emerged as a crucial tool for treating various types of cancer, including breast cancer. Pelareorep, for example, is an unchanged and intravenously conveyed oncolytic virus that entices an immune reaction in breast cancer survivors.

Startups Advancing Oncolytic Virus Cancer Therapy

The rising number of start-ups in the Oncolytic Virus Cancer Therapy Market has enhanced product quality and global sales. Furthermore, in order to gain a competitive edge, new start-ups are operating on recent developments and releasing new products such as:

  • AdCure Bio, a startup headquartered in the United States that offers cancer viro-immunotherapies, was established in 2016. AdCure Bio is a cancer viro-immunotherapy manufacturer in the pre-clinical stage that is evolving potent and secure immuno-stimulatory oncolytic viruses for solid tumor therapy.
  • Bionoxx, a South Korean startup established in 2016, evolves immune-oncology cancer treatments. The technologies developed by the startup integrates oncolytic vaccinia viruses, which ensure safety and maximize adaptive immunity. It encompasses a worldwide tumor-targeting antigen (UTTA) that strives out and destroys solid tumors along with remaining or recurring tumors.

Market Competition

Key players in the Oncolytic Virus Cancer Therapy Market are Oncolytics Biotech Inc., Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc. and ViroCure.

  • In August 2022, Amgen, based in the United States, agreed to spend $3.7 billion for the biopharma firm ChemoCentryx. Amgen will allow access to Tavneos, the firm's crucial therapy that has obtained therapy confirmation in the EU and Japan, as a result of this strategic initiative. With this procurement, Amgen can expand its reach and develop itself in regions such as Europe and the Asia Pacific.
  • Bristol Myers Squibb and PsiOxus Therapeutics expanded their collaboration in April 2021 to research PsiOxus Therapeutics' cancer-killing virus. The collaboration will integrate Bristol's checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors, based on the contract. NG-641 is based on the oncolytic virus 'enadenotucirev' developed by PsiOxus.
  • Enara Bio and Boehringer Ingelheim entered into a strategic partnership and licensing contract for the development of a novel aimed at cancer immunotherapy in January 2021. The new partnership merges Boehringer's strategy for cancer treatment, which integrates science with innovative platforms like oncolytic viruses and cancer, with Enara's competence in cancer antigen recognition.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 22.86 Million
Market Value in 2033 US$ 250 Million
Growth Rate CAGR of 27% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Virus Type
  • Application
  • End Use
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Oncolytics Biotech Inc.
  • Amgen Inc.
  • Sorrento Therapeutics
  • Transgene SA
  • Daiichi Sankyo Company
  • Shanghai Sunway Biotech Co Ltd
  • Takara Bio Inc.
  • PsiOxus Therapeutics
  • SillaJen Inc.
  • ViroCure
Customization Available Upon Request

Key Segments Profiled in the Oncolytic Virus Cancer Therapy Market Industry Survey

By Virus Type:

  • Genetically Engineered Oncolytic Viruses
    • Herpes Simplex Virus
    • Adenovirus
    • Vaccinia Virus
  • Oncolytic Wild-type Viruses
    • Reovirus
    • Newcastle Disease Virus
    • Vesicular Stomatitis Virus

By Application:

  • Solid Tumor
    • Breast Cancer
    • Prostate Cancer
    • Lung Cancer
    • Glioblastoma
  • Melanoma
    • Hematological Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma

By End Use:

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institutes

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the Expected CAGR for the Global Market?

The overall market is expected to advance at 27% CAGR until 2033.

What will be the Total Size of the Global Oncolytic Virus Cancer Therapy Market by 2033?

The total market size is expected to reach almost US$ 250 million by 2033.

Which End-user Category is the Leading Segment?

The hospitals or healthcare sector is projected to remain the leading end-user segment.

How will North America Market Perform During the Forecast Years?

North America to witness 29.5% CAGR through 2033.

Which are the Top Performing Oncolytic Virus Cancer Therapy Market Players?

Oncolytics Biotech, Amgen, and Serrento Therapeutics are the top service providers.

Table of Content

1. Executive Summary | Oncolytic Virus Cancer Therapy Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Virus Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Virus Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Virus Type, 2023 to 2033

        5.3.1. Genetically Engineered Oncolytic Viruses

            5.3.1.1. Herpes Simplex Virus

            5.3.1.2. Adenovirus

            5.3.1.3. Vaccinia Virus

        5.3.2. Oncolytic Wild-type Viruses

            5.3.2.1. Reovirus

            5.3.2.2. Newcastle Disease Virus

            5.3.2.3. Vesicular Stomatitis Virus

    5.4. Y-o-Y Growth Trend Analysis By Virus Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Virus Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Solid Tumors

            6.3.1.1. Breast Cancer

            6.3.1.2. Prostate Cancer

            6.3.1.3. Lung Cancer

            6.3.1.4. Glioblastoma

        6.3.2. Melanoma

            6.3.2.1. Hematological Malignancies

            6.3.2.2. Lymphoma

            6.3.2.3. Leukemia

            6.3.2.4. Myeloma

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-use

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Cancer Research Institutes

    7.4. Y-o-Y Growth Trend Analysis By End-use, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-use, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Virus Type

        9.2.3. By Application

        9.2.4. By End-use

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Virus Type

        9.3.3. By Application

        9.3.4. By End-use

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Virus Type

        10.2.3. By Application

        10.2.4. By End-use

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Virus Type

        10.3.3. By Application

        10.3.4. By End-use

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Virus Type

        11.2.3. By Application

        11.2.4. By End-use

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Virus Type

        11.3.3. By Application

        11.3.4. By End-use

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Virus Type

        12.2.3. By Application

        12.2.4. By End-use

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Virus Type

        12.3.3. By Application

        12.3.4. By End-use

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of Middle East and Africa(MEA)

        13.2.2. By Virus Type

        13.2.3. By Application

        13.2.4. By End-use

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Virus Type

        13.3.3. By Application

        13.3.4. By End-use

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Virus Type

            14.1.2.2. By Application

            14.1.2.3. By End-use

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Virus Type

            14.2.2.2. By Application

            14.2.2.3. By End-use

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Virus Type

            14.3.2.2. By Application

            14.3.2.3. By End-use

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Virus Type

            14.4.2.2. By Application

            14.4.2.3. By End-use

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Virus Type

            14.5.2.2. By Application

            14.5.2.3. By End-use

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Virus Type

            14.6.2.2. By Application

            14.6.2.3. By End-use

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Virus Type

            14.7.2.2. By Application

            14.7.2.3. By End-use

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Virus Type

            14.8.2.2. By Application

            14.8.2.3. By End-use

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Virus Type

            14.9.2.2. By Application

            14.9.2.3. By End-use

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Virus Type

            14.10.2.2. By Application

            14.10.2.3. By End-use

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Virus Type

            14.11.2.2. By Application

            14.11.2.3. By End-use

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Virus Type

            14.12.2.2. By Application

            14.12.2.3. By End-use

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Virus Type

            14.13.2.2. By Application

            14.13.2.3. By End-use

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Virus Type

            14.14.2.2. By Application

            14.14.2.3. By End-use

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Virus Type

            14.15.2.2. By Application

            14.15.2.3. By End-use

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Virus Type

            14.16.2.2. By Application

            14.16.2.3. By End-use

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Virus Type

            14.17.2.2. By Application

            14.17.2.3. By End-use

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Virus Type

            14.18.2.2. By Application

            14.18.2.3. By End-use

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Virus Type

            14.19.2.2. By Application

            14.19.2.3. By End-use

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Virus Type

            14.20.2.2. By Application

            14.20.2.3. By End-use

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Virus Type

        15.3.3. By Application

        15.3.4. By End-use

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Oncolytics Biotech Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Amgen Inc.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Sorrento Therapeutics

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Transgene SA

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Daiichi Sankyo Company

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Shanghai Sunway Biotech Co, Ltd

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Takara Bio Inc.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. PsiOxus Therapeutics

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. SillaJen Inc

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. ViroCure

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Oncology Adjuvants Market

Published : March 2023

Healthcare

Oncolytic Adenovirus Market

Published : December 2022

Healthcare

Oncology Apoptosis Modulators Market

Published : November 2022

Healthcare

Oncology Blood Testing Market

Published : July 2022

Explore Healthcare Insights

View Reports

Oncolytic Virus Cancer Therapy Market